Denali Therapeutics Inc.
- DNLI
- NASDAQ
- Biotechnology
- Neurodegenerative Therapies
- Biopharmaceutical R&D
$18.04
Today +2.44%Quote Oct 19, 2026, 08:00 PM UTC
−8.52%over the last month
Max drawdown −18.5%From 1-month high −16.5%3 months −24.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
503
Founded
2013
Market value
$2.88B
Quote Oct 19
Floor
$17.80
1.4% below price
Resistance
$18.20
0.9% above price
Price vs analyst targets
19 analysts
Lowest target
$26.00Highest target
$41.00
$26.00Highest target
$41.00
- Price $18.04
- Average target $33.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 87% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about DNLIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free